Back to News
Market Impact: 0.25
Ultralife Upgraded to Neutral on Backlog & Product Commercialization
Source: zacks.com
Analyst InsightsCompany FundamentalsCorporate Guidance & Outlook
ULBI was upgraded to Neutral, supported by a record backlog, product commercialization progress and manufacturing improvements. The upgrade also reflects broader growth opportunities from vertical integration, improving the company’s outlook but stopping short of a bullish rating.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ULBI0.55
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- ‘U.S. trade policy is damaging the U.S. auto industry’: Canada’s purchase of American cars hits new low as Trump’s tariffs backfire on U.S. automakers
- Beware borrowing costs: The jump in yields could hit these debt-laden stocks the most
- US court upholds Pentagon’s blacklisting of Anthropic
- Why Akamai Stock Is Up Today
- Ahead of U.S. IPO, British AI neocloud Nscale secures $3.36B in convertible finacing